2 withdrawn. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Medeor Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants MDR-103 - Kidney Transplant Rejection | Phase 2 | Withdrawn | Medeor Therapeutics, Inc. | 2024-12-01 | 2024-06-07 | |
| Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants MDR-102, Immunosuppressive Agents - Kidney Transplant Rejection | Phase 2 / Phase 3 | Withdrawn | Medeor Therapeutics, Inc. | 2024-12-01 | 2024-06-07 |
Adrenal Cortex Hormones (1) · Immunosuppressive Agents (1) · Mycophenolic Acid (1) · Tacrolimus (1)
Lenuta Micsa, MD (1)